<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01319747</url>
  </required_header>
  <id_info>
    <org_study_id>NL32865.044.10</org_study_id>
    <secondary_id>32865</secondary_id>
    <secondary_id>Dutch trial register entry</secondary_id>
    <nct_id>NCT01319747</nct_id>
  </id_info>
  <brief_title>Video-Assisted Thoracoscopic Pulmonary Vein Isolation Versus Percutaneous Catheter Ablation in Atrial Fibrillation Trial</brief_title>
  <acronym>VATCAT</acronym>
  <official_title>Video-Assisted Thoracoscopic Pulmonary Vein Isolation Versus Percutaneous Catheter Ablation in Atrial Fibrillation Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medisch Spectrum Twente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cardio Research Enschede BV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medisch Spectrum Twente</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies demonstrated that radiofrequency isolation of the pulmonary veins (PVI) and
      surgically video assisted thorascopic pulmonary vein isolation (VATS-PVI) are acceptable or
      even superior alternatives to antiarrhythmic drug therapy in patients with symptomatically
      paroxysmal atrial fibrillation (AF). However, data comparing effectiveness in both
      interventions are limited.

      The investigators want to compare the effectiveness of PVI and VATS-PVI. Secondary objectives
      are to compare the duration of hospitalization, quality of Life, cost and to compare the
      satisfaction of the patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inclusion rate insufficient
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of AF</measure>
    <time_frame>one year</time_frame>
    <description>The percentage of patients without a recurrence of AF, without antiarrhythmic drugs (AADs), within a follow-up period of at least 12 months after a stabilisation period of 90 days after the initial procedure. An episode of AF is defined as an episode of at least 30 seconds duration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment impact</measure>
    <time_frame>one year</time_frame>
    <description>Secondary objectives include the duration and cost of hospitalization, discomfort during admission, assessment and experienced AF burden during follow-up of procedural impact on the patient and time to recurrence after intervention. A complication register will also be kept.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Percutaneous therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VATS therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PVI</intervention_name>
    <description>For catheter ablation, we used irrigated 4mm RF-ablation catheters, at a maximum power of 30-35Watt, an irrigation rate of 20 mL/min. PV isolation was performed by wide circumferential ablation, encircling all ipsilateral PVs.</description>
    <arm_group_label>Percutaneous therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>VATS-PVI</intervention_name>
    <description>A bilateral video-assisted thoracoscopic (VATS) pulmonary vein isolation and left atrial appendage (LAA) excision is performed under general anaesthesia and double-lumen endotracheal ventilation.</description>
    <arm_group_label>VATS therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt; 18 years of age

          -  Documented, symptomatic, episodes of paroxysmal or persistent AF

          -  During the last 6 months patients must have at least 2 documented episodes of AF,
             despite the use of at least 1 anti arrhythmic drug.

          -  Able of providing informed consent

        Exclusion Criteria:

          -  Pregnancy

          -  Unwillingness to use or contra-indications for vitamin K antagonists

          -  Severely enlarged left atrium (&gt;50 mm) on echocardiography

          -  Prior AF ablation or AF surgery

          -  Intracardiac thrombus

          -  Prior heart surgery or pulmonary disease hampering thoracoscopic surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcoen Scholten, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medisch Spectrum Twente</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <state>OV</state>
        <zip>7500KA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2455</url>
    <description>Official dutch entry for VATCAT study</description>
  </link>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2011</study_first_submitted>
  <study_first_submitted_qc>March 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2011</study_first_posted>
  <last_update_submitted>July 6, 2016</last_update_submitted>
  <last_update_submitted_qc>July 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medisch Spectrum Twente</investigator_affiliation>
    <investigator_full_name>B. Oude Velthuis</investigator_full_name>
    <investigator_title>B. Oude Velthuis MD</investigator_title>
  </responsible_party>
  <keyword>atrial</keyword>
  <keyword>fibrillation</keyword>
  <keyword>pvi</keyword>
  <keyword>vats</keyword>
  <keyword>ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

